Roche’s US subsidiary Genentech breaks ground on state-of-the-art manufacturing facility in North Carolina, USA
Roche's (OTCQX:RHHBY) subsidiary Genentech has initiated construction of a $700 million manufacturing facility in Holly Springs, North Carolina. The 65,000 m² facility, set to be operational by 2029, represents Genentech's first East Coast manufacturing site and is part of Roche's larger $50 billion investment in US operations.
The strategic facility will focus on producing next-generation metabolic medicines, including obesity treatments, and is expected to create more than 1,900 jobs. Located on a 400,000 m² lot with expansion potential, the site was chosen for its skilled workforce, academic institutions, and proximity to other life science companies.
Genentech, controllata di Roche (OTCQX:RHHBY), ha avviato i lavori per costruire un impianto di produzione del valore di $700 milioni a Holly Springs, North Carolina. La struttura coprirà 65.000 m² e, prevista in funzione entro il 2029, sarà il primo sito di produzione di Genentech sulla Costa Est e rientra nel più ampio piano di investimenti di $50 miliardi di Roche negli Stati Uniti.
Il nuovo impianto sarà destinato alla produzione di farmaci metabolici di nuova generazione, compresi trattamenti per l'obesità, e dovrebbe generare oltre 1.900 posti di lavoro. Situato su un'area di 400.000 m² con possibilità di espansione, il sito è stato scelto per la disponibilità di personale qualificato, la vicinanza ad istituzioni accademiche e ad altre aziende nel settore delle scienze della vita.
Genentech, subsidiaria de Roche (OTCQX:RHHBY), ha comenzado la construcción de una planta de fabricación de $700 millones en Holly Springs, Carolina del Norte. La instalación, de 65.000 m² y prevista para entrar en servicio en 2029, será el primer centro de producción de Genentech en la Costa Este y forma parte de la inversión total de $50.000 millones de Roche en Estados Unidos.
La planta se centrará en producir medicamentos metabólicos de próxima generación, incluidos tratamientos contra la obesidad, y se espera que cree más de 1.900 puestos de trabajo. Ubicada en un terreno de 400.000 m² con capacidad de expansión, la localización se eligió por su mano de obra cualificada, la cercanía a instituciones académicas y a otras empresas de ciencias de la vida.
로슈(OTCQX:RHHBY)의 자회사 제넨텍(Genentech)이 노스캐롤라이나 홀리 스프링스에 7억 달러 규모의 제조시설 건설을 시작했습니다. 이 시설은 65,000 m² 규모로 2029년 가동을 목표로 하며, 제넨텍의 최초 동해안 제조기지로 로슈의 미국 내 500억 달러 투자 계획의 일환입니다.
해당 시설은 비만 치료제를 포함한 차세대 대사 질환 의약품 생산에 중점을 두며, 1,900명 이상의 일자리를 창출할 것으로 예상됩니다. 400,000 m² 부지에 확장 여지가 있으며, 숙련된 인력, 학계와의 근접성, 다른 생명과학 기업들과의 인접성 등이 부지 선정 이유로 꼽혔습니다.
Genentech, filiale de Roche (OTCQX:RHHBY), a lancé la construction d'une usine de production d'une valeur de 700 millions de dollars à Holly Springs, en Caroline du Nord. L'installation de 65 000 m², qui devrait être opérationnelle d'ici 2029, sera le premier site de production de Genentech sur la côte Est et s'inscrit dans le cadre du plan d'investissement de 50 milliards de dollars de Roche aux États-Unis.
Cette usine stratégique se consacrera à la fabrication de médicaments métaboliques de nouvelle génération, notamment des traitements contre l'obésité, et devrait permettre de créer plus de 1 900 emplois. Le site, situé sur un terrain de 400 000 m² offrant des possibilités d'expansion, a été choisi pour la qualité de sa main-d'œuvre, la proximité d'établissements académiques et d'autres entreprises des sciences de la vie.
Genentech, eine Tochtergesellschaft von Roche (OTCQX:RHHBY), hat mit dem Bau einer 700 Millionen Dollar teuren Produktionsanlage in Holly Springs, North Carolina begonnen. Die 65.000 m² große Anlage soll bis 2029 in Betrieb gehen und ist Genentechs erster Produktionsstandort an der Ostküste; sie ist Teil der größeren 50 Milliarden Dollar-Investition von Roche in den USA.
Die strategische Anlage wird sich auf die Herstellung von Medikamenten für Stoffwechselerkrankungen der nächsten Generation, einschließlich Adipositas-Behandlungen, konzentrieren und voraussichtlich mehr als 1.900 Arbeitsplätze schaffen. Das Gelände umfasst 400.000 m² mit Ausbaupotenzial und wurde wegen der qualifizierten Arbeitskräfte, der Nähe zu akademischen Einrichtungen und anderen Life-Sciences-Unternehmen ausgewählt.
- Investment of $700 million in new manufacturing facility demonstrates strong commitment to US market
- Creation of over 1,900 new jobs in North Carolina
- Strategic expansion into East Coast manufacturing enhances supply chain resilience
- Facility designed for future expansion with 400,000 m² lot space available
- Part of larger $50 billion investment commitment in US operations
- Long timeline to operational status - facility not expected to be functional until 2029
- Significant capital expenditure may impact short-term financial flexibility
- The
$700 million project is part of Roche’s$50 billion investment in US manufacturing, infrastructure and R&D. - The facility will create more than 1,900 jobs and support the production of next-generation metabolic medicines, including treatments for obesity
- These investments underscore Roche’s commitment to innovative manufacturing, designed to bring life-changing treatments to patients faster
Basel, 25 August 2025 - Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today broke ground on its newest US manufacturing site in Holly Springs, North Carolina. This significant development marks the establishment of Genentech’s first manufacturing facility on the East Coast. The 65,000 m² facility is strategically designed to support production of the company’s future portfolio of metabolic medicines, including next-generation treatments for obesity.
Genentech’s initial investment in North Carolina is estimated at more than
Roche Group CEO Thomas Schinecker:
“I am proud to break ground on our new state-of-the-art manufacturing facility in North Carolina, which will support the production of our next-generation obesity treatments. This
The company selected Holly Springs in North Carolina, a growing hub for biopharmaceutical innovation, for its highly skilled local workforce, strong academic institutions and proximity to other leading life science companies.
The new facility is expected to be completed and operational by 2029, incorporating modern biomanufacturing technologies, as well as advanced automation and digital capabilities. The 400,000 m² lot includes space for future expansion.
Designed for high-volume, efficient, and sustainable production, the new facility will increase Roche’s manufacturing capacity and enhance supply chain resilience. It complements Roche’s manufacturing sites around the world, including in Europe and Switzerland, to efficiently serve patients where they are.
About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.
For over 125 years, sustainability has been an integral part of Roche’s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.
Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com
| Hans Trees, PhD Phone: +41 79 407 72 58 | Sileia Urech Phone: +41 79 935 81 48 |
| Nathalie Altermatt Phone: +41 79 771 05 25 | Lorena Corfas Phone: +41 79 568 24 95 |
| Simon Goldsborough Phone: +44 797 32 72 915 | Karsten Kleine Phone: +41 79 461 86 83 |
| Kirti Pandey Phone: +49 172 6367262 | Yvette Petillon Phone: +41 79 961 92 50 |
| Dr Rebekka Schnell Phone: +41 79 205 27 03 |
Attachment
FAQ
How much is Roche investing in the new North Carolina manufacturing facility?
How many jobs will Roche's new North Carolina facility create?
When will Roche's new Holly Springs manufacturing facility be operational?
What types of medicines will be produced at Roche's new North Carolina facility?
How large is Roche's new manufacturing facility in Holly Springs?
